Will FDA Observations Fog Speculated Claris Deal?
This article was originally published in PharmAsia News
Executive Summary
Claris, the Indian injectables maker, has recently been served five observations by the U.S. FDA related to its manufacturing practices in India. The action coincides with a speculated deal for the firm’s U.S. businesses which analysts believe may now face obstructions due to the regulatory uncertainty.